Nurix’s $175M offering; Invivyd CEO is out

Plus, news about Agenus, Gerresheimer and Oculis:

Nurix Therapeutics’ $175M offering: The protein degrader biotech upsized its stock sale, which it will use primarily to fund studies of its three early-stage clinical drug candidates, including two protein degraders for B-cell malignancies. Nurix’s shares $NRIX jumped by around 11% in the past month after the company announced research deal extensions with both Gilead and Sanofi, though the stock fell about 6% Friday morning. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Make the Diagnosis: Be Careful–Really Careful–With Heating Pads

Presentation A 38-year-old woman visited her doctor for discoloration that had developed on her trunk 2 months prior. On examination, extensive hyperpigmented, reticulated patches were

September 19, 2023

The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer

Molecularly targeted therapy is proving promising for endometrial cancer. Not only are molecular tests able to group or split endometrial cancers into specific molecular groups,

July 6, 2024

athenahealth Appoints David Minkin General Manager of epocrates

David Minikin, General Manager at epocrates What You Should Know: – athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.